A Systematic Review on the Efficacy and Safety of Chloroquine for the Treatment of COVID-19
et al., J. Crit. Care, June 2020, 57:279-283, doi:10.1016/j.jcrc.2020.03.005, Epub Mar 10, 2020, Mar 2020
HCQ for COVID-19
1st treatment shown to reduce risk in
March 2020, now with p < 0.00000000001 from 424 studies, used in 59 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,200+ studies for
200+ treatments. c19early.org
|
Review of six articles and 23 ongoing clinical trials in China recommending research and clinical use adhering to MEURI.
9 meta analyses show significant improvements with hydroxychloroquine for mortality1-4,
hospitalization1,
recovery5,
combined death/hospitalization/cases6,
cases7,8, and
viral clearance9.
Currently there are 38 HCQ for COVID-19 early treatment studies, showing 76% lower mortality [61‑85%], 67% lower ventilation [-710‑99%], 31% lower ICU admission [1‑53%], and 41% lower hospitalization [28‑51%].
1.
Landsteiner de Sampaio Amêndola et al., COVID-19 Infection in Rheumatic Patients on Chronic Antimalarial Drugs: A Systematic Review and Meta-Analysis, Journal of Clinical Medicine, doi:10.3390/jcm11226865.
2.
Risch, H., Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis, American Journal of Epidemiology, kwaa093, 27 May 2020, doi:10.1093/aje/kwaa093.
3.
Risch (B), H., Response to: “Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients” and “Re: Early Outpatient Treatment of Symptomatic, High-Risk Covid-19 Patients that Should be Ramped-Up Immediately as Key to the Pandemic Crisis”, American Journal of Epidemiology, July 20, 2020, doi:10.1093/aje/kwaa152.
4.
Stricker et al., Hydroxychloroquine Pre-Exposure Prophylaxis for COVID-19 in Healthcare Workers from India: A Meta-Analysis, Journal of Infection and Public Health, doi:10.1016/j.jiph.2021.08.001.
5.
Prodromos et al., Hydroxychloroquine is effective, and consistently so used early, for Covid-19: A systematic review, New Microbes and New Infections, doi:10.1016/j.nmni.2020.100776.
6.
Ladapo et al., Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in the Prevention of COVID-19 Infection, Hospitalization, and Death: Meta-Analysis, medRxiv, doi:10.1101/2020.09.30.20204693.
7.
García-Albéniz et al., Systematic review and meta-analysis of randomized trials of hydroxychloroquine for the prevention of COVID-19, European Journal of Epidemiology, doi:10.1007/s10654-022-00891-4.
Cortegiani et al., 10 Mar 2020, peer-reviewed, 5 authors.
A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
Journal of Critical Care, doi:10.1016/j.jcrc.2020.03.005
Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19
Authors' contribution AC conceived the content, retrieved the data, wrote the manuscript and approved the final version. MI retrieved the data, wrote the manuscript and approved the final version. GI retrieved the data, wrote the manuscript and approved the final version. AG conceived the content, helped in data extraction, revised the manuscript critically and approved the final version. SE conceived the content, helped in data extraction, wrote the manuscript and approved the final version.
Appendix A. Supplementary data Supplementary data to this article can be found online at https://doi. org/10.1016/j.jcrc.2020.03.005.
References
Colson, Rolain, Raoult, Chloroquine for the 2019 novel coronavirus SARS-CoV-2, Int J Antimicrob Agents
Gao, Tian, Yang, Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047
Guan, Ni, Hu, Liang, Ou et al., Clinical Characteristics of Coronavirus Disease 2019 in China, N Engl J Med, doi:10.1056/NEJMoa2002032
Huang, Wang, Li, Ren, Zhao et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet
Lenk, Duttge, Ethical and legal framework and regulation for off-label use: European perspective, Ther Clin Risk Manag
Savarino, Boelaert, Cassone, Majori, Cauda, Effects of chloroquine on viral infections: an old drug against today's diseases?, Lancet Infect Dis
Wang, Cao, Zhang, Yang, Liu et al., Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, doi:10.1038/s4142202002820
Wang, Hu, Hu, Zhu, Liu et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in, doi:10.1001/jama.2020.1585
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease, doi:10.1001/jama.2020.2648
Yang, Yu, Xu, Shu, Xia et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study, Lancet Respir Med, doi:10.1016/S2213-2600(20)30079-5
DOI record:
{
"DOI": "10.1016/j.jcrc.2020.03.005",
"ISSN": [
"0883-9441"
],
"URL": "http://dx.doi.org/10.1016/j.jcrc.2020.03.005",
"alternative-id": [
"S0883944120303907"
],
"assertion": [
{
"label": "This article is maintained by",
"name": "publisher",
"value": "Elsevier"
},
{
"label": "Article Title",
"name": "articletitle",
"value": "A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19"
},
{
"label": "Journal Title",
"name": "journaltitle",
"value": "Journal of Critical Care"
},
{
"label": "CrossRef DOI link to publisher maintained version",
"name": "articlelink",
"value": "https://doi.org/10.1016/j.jcrc.2020.03.005"
},
{
"label": "Content Type",
"name": "content_type",
"value": "article"
},
{
"label": "Copyright",
"name": "copyright",
"value": "© 2020 Elsevier Inc. All rights reserved."
}
],
"author": [
{
"affiliation": [],
"family": "Cortegiani",
"given": "Andrea",
"sequence": "first"
},
{
"affiliation": [],
"family": "Ingoglia",
"given": "Giulia",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Ippolito",
"given": "Mariachiara",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Giarratano",
"given": "Antonino",
"sequence": "additional"
},
{
"affiliation": [],
"family": "Einav",
"given": "Sharon",
"sequence": "additional"
}
],
"container-title": "Journal of Critical Care",
"container-title-short": "Journal of Critical Care",
"content-domain": {
"crossmark-restriction": true,
"domain": [
"clinicalkey.jp",
"clinicalkey.com",
"clinicalkey.es",
"clinicalkey.com.au",
"clinicalkey.fr",
"elsevier.com",
"sciencedirect.com"
]
},
"created": {
"date-parts": [
[
2020,
3,
10
]
],
"date-time": "2020-03-10T16:37:37Z",
"timestamp": 1583858257000
},
"deposited": {
"date-parts": [
[
2020,
6,
10
]
],
"date-time": "2020-06-10T14:30:25Z",
"timestamp": 1591799425000
},
"indexed": {
"date-parts": [
[
2024,
5,
13
]
],
"date-time": "2024-05-13T12:40:42Z",
"timestamp": 1715604042255
},
"is-referenced-by-count": 659,
"issued": {
"date-parts": [
[
2020,
6
]
]
},
"language": "en",
"license": [
{
"URL": "https://www.elsevier.com/tdm/userlicense/1.0/",
"content-version": "tdm",
"delay-in-days": 0,
"start": {
"date-parts": [
[
2020,
6,
1
]
],
"date-time": "2020-06-01T00:00:00Z",
"timestamp": 1590969600000
}
}
],
"link": [
{
"URL": "https://api.elsevier.com/content/article/PII:S0883944120303907?httpAccept=text/xml",
"content-type": "text/xml",
"content-version": "vor",
"intended-application": "text-mining"
},
{
"URL": "https://api.elsevier.com/content/article/PII:S0883944120303907?httpAccept=text/plain",
"content-type": "text/plain",
"content-version": "vor",
"intended-application": "text-mining"
}
],
"member": "78",
"original-title": [],
"page": "279-283",
"prefix": "10.1016",
"published": {
"date-parts": [
[
2020,
6
]
]
},
"published-print": {
"date-parts": [
[
2020,
6
]
]
},
"publisher": "Elsevier BV",
"reference": [
{
"DOI": "10.1001/jama.2020.2648",
"article-title": "Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention",
"author": "Wu",
"doi-asserted-by": "crossref",
"journal-title": "Jama",
"key": "10.1016/j.jcrc.2020.03.005_bb0005",
"year": "2020"
},
{
"DOI": "10.1016/S1473-3099(03)00806-5",
"article-title": "Effects of chloroquine on viral infections: an old drug against today’s diseases?",
"author": "Savarino",
"doi-asserted-by": "crossref",
"first-page": "722",
"journal-title": "Lancet Infect Dis",
"key": "10.1016/j.jcrc.2020.03.005_bb0010",
"volume": "3",
"year": "2003"
},
{
"DOI": "10.1016/j.ijantimicag.2020.105923",
"article-title": "Chloroquine for the 2019 novel coronavirus SARS-CoV-2",
"author": "Colson",
"doi-asserted-by": "crossref",
"first-page": "105923",
"journal-title": "Int J Antimicrob Agents",
"key": "10.1016/j.jcrc.2020.03.005_bb0015",
"year": "2020"
},
{
"DOI": "10.5582/bst.2020.01047",
"article-title": "Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies",
"author": "Gao",
"doi-asserted-by": "crossref",
"journal-title": "Biosci Trends",
"key": "10.1016/j.jcrc.2020.03.005_bb0025",
"year": "2020"
},
{
"article-title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro",
"author": "Wang",
"journal-title": "Cell Res",
"key": "10.1016/j.jcrc.2020.03.005_bb0030",
"year": "2020"
},
{
"article-title": "Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia",
"journal-title": "Zhonghua Jie He He Hu Xi Za Zhi",
"key": "10.1016/j.jcrc.2020.03.005_bb0035",
"volume": "43",
"year": "2020"
},
{
"DOI": "10.1056/NEJMoa2002032",
"article-title": "Clinical Characteristics of Coronavirus Disease 2019 in China",
"author": "Guan",
"doi-asserted-by": "crossref",
"journal-title": "N Engl J Med",
"key": "10.1016/j.jcrc.2020.03.005_bb0060",
"year": "2020"
},
{
"DOI": "10.1001/jama.2020.1585",
"article-title": "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China",
"author": "Wang",
"doi-asserted-by": "crossref",
"journal-title": "Jama",
"key": "10.1016/j.jcrc.2020.03.005_bb0065",
"year": "2020"
},
{
"DOI": "10.1016/S2213-2600(20)30079-5",
"article-title": "Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study",
"author": "Yang",
"doi-asserted-by": "crossref",
"journal-title": "Lancet Respir Med",
"key": "10.1016/j.jcrc.2020.03.005_bb0070",
"year": "2020"
},
{
"DOI": "10.1016/S0140-6736(20)30183-5",
"article-title": "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China",
"author": "Huang",
"doi-asserted-by": "crossref",
"first-page": "497",
"journal-title": "Lancet",
"key": "10.1016/j.jcrc.2020.03.005_bb0075",
"volume": "395",
"year": "2020"
},
{
"DOI": "10.2147/TCRM.S40232",
"article-title": "Ethical and legal framework and regulation for off-label use: European perspective",
"author": "Lenk",
"doi-asserted-by": "crossref",
"first-page": "537",
"journal-title": "Ther Clin Risk Manag",
"key": "10.1016/j.jcrc.2020.03.005_bb0090",
"volume": "10",
"year": "2014"
}
],
"reference-count": 11,
"references-count": 11,
"relation": {},
"resource": {
"primary": {
"URL": "https://linkinghub.elsevier.com/retrieve/pii/S0883944120303907"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19",
"type": "journal-article",
"update-policy": "http://dx.doi.org/10.1016/elsevier_cm_policy",
"volume": "57"
}